Physician profile
Gary E Goff
NPI 1629050521
$16,579.98
in general payments reported to CMS, 2019-2025
73 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,520 · 2020: $2,122 · 2021: $2,421 · 2022: $2,547 · 2023: $2,079 · 2024: $1,902 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,969.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,364.34 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,494.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,421.87 | 2020-2025 | |
| Amgen INC. | $1,383.47 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,003.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $886.72 | 2019-2023 | |
| Pfizer INC. | $755.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $634.64 | 2019-2023 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $570.17 | 2019-2025 | Camzyos, Eliquis |
| Lilly USA, LLC | $526.56 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.71 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Novartis Pharmaceuticals Corporation | $436.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $433.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $407.04 | 2021-2025 | |
| Heartflow, INC. | $297.97 | 2021-2025 | Ffrct |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.